ABIRISK Making novel drugs safer for patients A growing number of medicines are based on biological molecules such as proteins and monoclonal antibodies. These novel drugs have resulted in new, more effective treatments

First Page		Document Content
Date: 2012-11-23 07:10:19 Pharmaceutical industry Pharmacy Pharmaceuticals policy Biotechnology Immunogenicity Immunology European Federation of Pharmaceutical Industries and Associations Biopharmaceutical Novartis Sanofi Pharmaceutical drug Drug development		ABIRISK Making novel drugs safer for patients A growing number of medicines are based on biological molecules such as proteins and monoclonal antibodies. These novel drugs have resulted in new, more effective treatments Add to Reading List Source URL: www.abirisk.eu Download Document from Source Website File Size: 124,66 KB Share Document on Facebook

	RETAIL PHARMACY CASE STUDY Retail Pharmacy and Healthcare Distributor Case Study Global powerhouse gains visibility, strategic power and clarity with KeyedIn Projects SaaS solution DocID: 1xVz3 - View Document
	Case Study: WESTERN MARYLAND PHARMACY Improving Clinical Outcomes and Decreasing Acetaminophen Costs by 78% with Diver Platform DocID: 1xTm3 - View Document
	PDF Document DocID: 1xQi5 - View Document
	PDF Document DocID: 1xNTr - View Document
	PDF Document DocID: 1xIyF - View Document